Unlocking the Potential of FAM83C-AS1: A drug Target and Biomarker for the Treatment of Cancer

Target Name: FAM83C-AS1

NCBI ID: G140846

FAM83C-AS1

Other Name(s): NCRNA00154 | dJ614O4.3 | FAM83C antisense RNA 1 | C20orf120

Unlocking the Potential of FAM83C-AS1: A drug Target and Biomarker for the Treatment of Cancer

Introduction

Cancer is one of the leading causes of morbidity and mortality worldwide, affecting millions of individuals across the globe. The development of new treatments for cancer has become a major focus of research in the past few decades. Among the many drug targets and biomarkers that have been identified, FAM83C-AS1 stands out as a promising candidate for cancer treatment. In this article, we will explore the potential of FAM83C-AS1 as a drug target and biomarker for cancer.

FAM83C-AS1: A drug target and biomarker

FAM83C-AS1 is a non-coding RNA (ncRNA) that has been identified in various studies as having potential as a drug target and biomarker for cancer. FAM83C-AS1 is a part of the microRNA (miRNA) family, which is a group of small non-coding RNAs that play a critical role in post-transcriptional gene regulation. miRNAs have been shown to play a significant role in cancer development and progression by regulating various cellular processes, including cell growth, apoptosis, and angiogenesis.

FAM83C-AS1 functions as a negative regulator of the Runx1 gene, which is a key regulator of cell growth and differentiation. By inhibiting the activity of Runx1, FAM83C-AS1 has been shown to induce cell cycle arrest and apoptosis in various cancer cell lines. This property makes FAM83C-AS1 an attractive drug target for cancer treatment.

Furthermore, FAM83C-AS1 has also been shown to act as a biomarker for cancer. The expression of FAM83C-AS1 has been shown to be downregulated in various types of cancer, including breast, lung, and ovarian cancer. This downregulation has been associated with poor prognosis and poorer patient outcomes. Therefore, targeting FAM83C-AS1 as a drug or biomarker for cancer has the potential to improve treatment outcomes for cancer patients.

The potential mechanisms of FAM83C-AS1 as a drug target and biomarker for cancer are:

1. Inhibition of Runx1: FAM83C-AS1 has been shown to inhibit the activity of Runx1, which is a key regulator of cell growth and differentiation. This inhibition leads to the accumulation of cells stuck in G1 phase, which can lead to the formation of apoptosis-prone cells. By inhibiting cell growth and apoptosis, FAM83C-AS1 may contribute to the anti-cancer effects of the drug.
2. MicroRNA targeting: FAM83C-AS1 is part of the miRNA family, which is a group of small non-coding RNAs that play a critical role in post-transcriptional gene regulation. By targeting specific miRNAs, FAM83C-AS1 may contribute to the anti- -cancer effects of the drug.
3. Epigenetic modulation: FAM83C-AS1 has been shown to interact with the histone modification complex, which is involved in the epigenetic regulation of gene expression. By modulating the histone modification complex, FAM83C-AS1 may contribute to the anti-cancer effects of the drug.

Conclusion

FAM83C-AS1 is a promising candidate as a drug target and biomarker for cancer. Its ability to inhibit the activity of Runx1 and to act as a biomarker for cancer has significant implications for cancer treatment. Further studies are needed to fully understand the anti-cancer effects of FAM83C-AS1 and its potential as a drug target and biomarker for cancer.

Protein Name: FAM83C Antisense RNA 1

The "FAM83C-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM83C-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets